Tumor Microenvironment Programs
Cancer
PreclinicalActive
Key Facts
About Xyphos
Xyphos Biosciences is a private, preclinical-stage biotech company pioneering a novel and adaptable platform for cancer cell therapy. The company's core technology is the convertibleCAR platform, which aims to address key limitations of current CAR-T therapies by enabling control over T-cell activity and targeting multiple antigens. Led by an experienced team with deep expertise in oncology and drug development, Xyphos is working to advance its platform towards clinical development for a variety of cancer indications.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Not Specified (Oncology Focus) | Narwhal Bio | Pre-clinical |
| EDM Platform for Genetic Medicine | Coastar Therapeutics | Pre-clinical |
| CO-1 | Caedo Oncology | Pre-clinical |
| Anti-CD99 monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Anti-HLA class I monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Triapine® | Nanopharmaceutics | Clinical |
| Ammonium Tetrathiomolybdate | Nanopharmaceutics | Clinical |
| Aza-TdC | Nanopharmaceutics | Clinical |
| Undisclosed Oncology Program(s) | Cell BioEngines | Phase 1 |
| No-alpha IL-2 Mutein | SarcoMed USA | Pre-clinical |
| PMIS Therapeutic | NaturemiRI | Preclinical/Clinical (unspecified) |
| AUM302 (formerly IBL-302) | Inflection Biosciences | Pre-clinical (partnered) |